AVEO Pharma

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec. The company was established in 2001 and is based in Cambridge, Massachusetts.

AVEO (AVEO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Can AVEO (AVEO) Run Higher on Strong Earnings Estimate Revisions?

AVEO: Drug Approved, But Still A Long Way To Go Before Self Sufficiency

AVEO (AVEO) delivered earnings and revenue surprises of -15.79% and -70.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Lags Revenue Estimates

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update. “The U.S. Food and Drug Administration's (FDA) recent approval of FOTIVDA marks a transformative event for AVEO, and we are eager to demonstrate FOTIVDA's potential to serve as a meaningful new treatment option within the growing relapsed or refractory advanced renal cell carcinoma (RCC) patient population. We look forward to bringing t

AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update

Bristol-Myers

AVEO forges an alliance with Bristol Myers to evaluate Fotivda in combination with Opdivo for RCC.

AVEO Collaborates with Bristol Myers to Conduct Combo Study

AVEO Pharmaceuticals Inc's (NASDAQ: AVEO) brief positive news of getting FDA approval for Tivozanib in relapsed kidney cancer this month was upset after its partner CANbridge Life Sciences voluntarily terminated the collaboration agreement. The company said it would “regain its rights” to the investigational cancer med AV-203 outside North America from early September.

AVEO Pharmaceuticals, CANbridge AV-203 Licensing Deal Axed, AVEO Regains Ex-North American Rights

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it will regain its rights to AV-203 outside of North America, its clinical-stage potent humanized IgG1 monoclonal antibody that targets ErbB3 (also known as HER3), following the voluntary termination of its collaboration and license agreement by CANbridge Life Sciences. AVEO will regain rights to AV-203 in all territories outside of North America, and CANbridge has initiated the process to transfer all preclinical data a

AVEO Oncology to Regain Ex-North American Rights to AV-203

AVEO Pharmaceuticals Inc (NASDAQ: AVEO) has entered into a collaboration and supply agreement with Bristol-Myers Squibb Co (NYSE: BMY) to evaluate the former's Fotivda (tivozanib) in combination with the latter's Opdivo (nivolumab). The Phase 3 TiNivo-2 trial will enroll around 326 patients with advanced relapsed or refractory renal cell carcinoma following prior immunotherapy exposure.

Aveo Pharma's Tivozanib To Be Tested In Combination With Opdivo In Kidney Cancer

The stock price of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) has increased by over 5% pre-market. This is why it happened.

AVEO Stock Price Increases Over 5% Pre-Market: Why It Happened

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate FOTIVDA® (tivozanib) in combination with OPDIVO® (nivolumab), Bristol Myers Squibb's anti-PD-1 therapy, in the pivotal Phase 3 TiNivo-2 trial in patients with advanced relapsed or refractory renal cell carcinoma (RCC) following prior immunotherapy exposure. FOTIVDA is an oral, next-generation vascular endothelial

AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma

Hercules Capital

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates. This second tranche was made available in connection with the recent U.S. Food and Drug Administration (FDA) approval of FOTIVDA® (tivozanib). “With the additional $20 million now available to us from Hercules, AVEO is well positioned to

AVEO Oncology Announces Drawdown of $20 Million Tranche Under Hercules Debt Facility

Coupang

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Thinking About Buying CPNG Stock, MDMP Stock Or AVEO Stock?

Aveo Pharmaceuticals Inc. (NASDAQ: AVEO) shares are trading higher Thursday after the company received FDA approval for Fotivda for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma on Wednesday evening. After a higher open Thursday morning, the stock was down 15.58% at $12.90 at last check.

Aveo Pharmaceuticals Stock Volatile After FDA Approval: Technical Levels To Watch

Shares of Aveo climbed 17% early Thursday, stretching their run higher after the company won US regulatory approval for its renal cancer treatment Fotivda. The stock on Wednesday soared 89% and was subject to two trading halts. Shares closed at $15.28.  The two-day move higher came after the Food and Drug Administration on Wednesday approved the company's Fotivda treatment for adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies.

Aveo extends gains to 106% after drug maker wins FDA approval for kidney cancer treatment (AVEO)

The FDA has finally approved AVEO Pharmaceuticals Inc's (NASDAQ: AVEO) tivozanib for advanced renal cell carcinoma, nine years after it first submitted its marketing application to the agency. The label covers relapsed or refractory renal cell carcinoma who have received two or more prior systemic therapies.

Aveo Pharma's Stock Trading Higher On Much Awaited FDA Approval For Tivozanib In Relapsed Kidney Cancer

The stock price of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) has increased by over 20% pre-market. This is why it happened.

AVEO Stock Price Increases Over 20% Pre-Market: Why It Happened

AVEO (AVEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AVEO (AVEO) Stock Jumps 89.1%: Will It Continue to Soar?

The stock price of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) increased by 89.11%. This is why it happened.

AVEO Stock Price Increased 89.11%: Why It Happened

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO's commercial strategy and operations, including the commercialization of FOTIVDA® (tivozanib). FOTIVDA is AVEO's differentiated oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved in the U.S. for the treatment of adult patients with relapsed or refractor

AVEO Announces Appointment of Mike Ferraresso to Chief Commercial Officer

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA® (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies. FOTIVDA is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). “Today's approval of FOTIVDA provides a new tool for treating patients with kidney canc

AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AVEO Pharmaceuticals (AVEO) Q4 Earnings Expected to Decline

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually on March 9-10, 2021. A replay of the pre-recorded presentation can be accessed on Tuesday, March 9, 2021 in the investors section of the Company's website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date. About

AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:00 p.m. Eastern Time. A live webcast of the fireside chat can be accessed by visiting the investors section of the Company's website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentatio

AVEO Oncology Announces Participation at the 2021 SVB Leerink Global Healthcare Conference

BOSTON, Mass.--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the presentation of two analyses of the Company's pivotal TIVO-3 study, its Phase 3 trial comparing tivozanib, AVEO's next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, to sorafenib in third- and fourth-line renal cell carcinoma (RCC). The data are being presented in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2021 Genit

AVEO Oncology Announces Presentation of Key Subgroup and Quality of Life Analyses from the Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates, to be added to the current tranched, $35 million debt facility secured with Hercules in August 2020 through an amendment to the amended and restated loan and security agreement (the “Loan Agreement”). Terms of the facility would remain otherwise unchanged from the Loan Agreement

AVEO Oncology Announces Commitment for an Incremental $10 Million Loan in Addition to Current Tranched, $35 Million Debt Facility with Hercules Capital

News for AVEO Pharma Stock (AVEO)